Maitake & Immune Health
1.2–1.4x immune enhancement
Cancer patients taking MD-fraction alongside chemotherapy showed immune cell activity 1.2 to 1.4 times higher than chemotherapy alone, in the foundational MD-fraction clinical study.
Nanba et al., Alternative Therapies in Health and Medicine, 2002
58–69%
symptom improvement rate across cancer types (Nanba 2002)
2 pathways
dectin-1 and TLR4 both activate dendritic cells
3 mg/kg
twice-daily dose with strongest stimulatory effects (Deng 2009)
Nanba et al., Alternative Therapies in Health and Medicine, 2002
View as image ↗In 2002, researcher Hiroaki Nanba published data that became the foundational reference for MD-fraction clinical research: cancer patients taking MD-fraction alongside chemotherapy showed immune cell activity 1.2 to 1.4 times higher than those on chemotherapy alone.[1] That study, now more than two decades old, remains the primary clinical paper to directly test MD-fraction as a formulated product.
MD-fraction is an enhanced version of maitake's better-known D-fraction. It is a liquid extract derived from the same beta-glucan polysaccharides, developed by Nanba with a vitamin C co-administration strategy intended to improve absorption through the gut. Most of the underlying immune research for maitake was conducted using D-fraction. MD-fraction's proponents argue it delivers the same biological effects more reliably, because the liquid form reaches the bloodstream more efficiently.
This article focuses on what MD-fraction is, how it differs from D-fraction, and what the research shows about its effects on dendritic cells: the immune messengers that connect the body's rapid first-response system to its long-term, targeted defenses. For a broader introduction to maitake and its bioactive compounds, see our complete maitake overview.
Key Takeaways
- Maitake MD-fraction is a liquid version of D-fraction, co-formulated with vitamin C to improve absorption; both are derived from maitake's beta-1,3/1,6-glucan polysaccharide, sharing the same active immune-activating compound
- In a non-randomized trial, cancer patients taking MD-fraction plus chemotherapy showed immune cell activity 1.2 to 1.4 times higher than chemotherapy alone, with 58 to 69 percent symptom improvement depending on cancer type (Nanba 2002)
- Two distinct molecular pathways activate dendritic cells: maitake alpha-glucan works through a receptor called dectin-1, while a separate maitake protein works through TLR4, a receptor that normally detects bacterial danger signals (Masuda 2019; Tsao 2013)
- In the only human dose-escalation study, the strongest immune stimulatory effects appeared at 3 mg/kg twice daily; higher doses produced immune-suppressive effects in some measures in the same patient population (Deng 2009)
- The most rigorous clinical trial, Hu et al. (2022), found that D-fraction supplementation improved NK cell and T-cell counts in head and neck cancer patients undergoing concurrent chemoradiotherapy
- Direct head-to-head clinical comparison of MD-fraction versus D-fraction in human pharmacokinetic trials has not been published; the bioavailability advantage of MD-fraction is based on formulation logic rather than measured human absorption data
What Separates MD-Fraction From D-Fraction
Maitake's most studied bioactive compounds are its beta-glucans: complex polysaccharide chains that form part of the fungal cell wall. The specific structure found in maitake is a beta-1,3/1,6-glucan, named for the way its sugar units branch and connect. This branching pattern is what allows the molecule to activate a specific class of immune receptors. The "fraction" research in maitake is essentially a decades-long project to isolate, concentrate, and optimize this polysaccharide for consistent immune effects.
D-fraction is the original concentrated extract, typically produced as a dry powder or tablet. MD-fraction is a later formulation developed by Nanba, the researcher who first isolated D-fraction in the 1980s. The core innovation: a liquid extraction process that Nanba argued produced higher concentrations of active polysaccharide, combined with vitamin C co-administration. The vitamin C serves a functional purpose in this context, protecting the beta-glucan compound from oxidation during storage and improving uptake across the gastrointestinal lining.
A 2021 review by Wu et al. in Foods catalogued all three major maitake fractions systematically: D-fraction (the foundation of immune and antitumor research since the 1980s), SX-fraction (associated with blood sugar regulation), and MD-fraction (an enhanced-bioavailability formulation of D-fraction's active compounds).[2] The review notes MD-fraction's higher bioavailability claim but is careful to flag that this claim rests primarily on formulation theory and animal absorption data rather than a controlled human comparison.
In biological terms, D-fraction and MD-fraction share the same active compound. The question is whether the body receives more of it per dose with MD-fraction's liquid delivery. For the consumer, the distinction matters when selecting a product. For the researcher evaluating clinical evidence, it matters less: the mechanism is the same, and the clinical trials that exist used D-fraction. For background on how maitake's beta-glucan compounds interact with the immune system more broadly, see Maitake and Immune Health.
Two Pathways to Dendritic Cell Activation
Dendritic cells are the immune system's information carriers. They patrol body tissues, sample antigens from pathogens or from damaged cells, mature into a fully activated state, and then travel to lymph nodes to present what they found to T-cells. That briefing of T-cells is what activates the adaptive immune system: the precise, slow-building arm of immunity that creates targeted, long-term responses to specific threats. A compound that triggers dendritic cell maturation is, in theory, a compound that helps the immune system recognize and remember threats more effectively.
Maitake activates dendritic cells through at least two distinct molecular signals, and the fact that there are two is part of what makes the research compelling.
The first pathway involves maitake's beta-glucan binding to a surface receptor called dectin-1. This receptor evolved to detect fungal cell wall components, which means maitake's polysaccharide is, in a sense, speaking the language that dectin-1 was built to hear. Li et al. (2014) reviewed the full downstream cascade in a systematic analysis: when fungal beta-glucans bind dectin-1 on macrophages and dendritic cells, the cell engulfs the target through phagocytosis (direct destruction), produces reactive oxygen species that kill pathogens, and releases a set of cytokines including IL-6, TNF-alpha, and IL-12.[3] These cytokines are chemical signals that prime NK cells and T-cells downstream, connecting the innate response to the adaptive one.
The second pathway does not involve beta-glucan at all. Tsao et al. (2013) characterized a novel protein from maitake, completely distinct from the polysaccharide fractions, that activated both NK cells and dendritic cells through TLR4: a surface receptor that normally detects bacterial cell wall components, not fungal ones.[5] This maitake protein appears to trigger the same alarm that bacteria do, causing dendritic cells to treat the encounter as a threat and mature accordingly. When these TLR4-activated dendritic cells were loaded with a tumor antigen and used as a vaccine in mice, tumor growth was significantly reduced compared to controls.
Masuda et al. (2019) confirmed the dectin-1 route using a specific maitake alpha-glucan called YM-2A.[4] Dendritic cells exposed to YM-2A showed morphological changes that are hallmarks of maturation: extended projections that increase surface area for antigen presentation, upregulation of surface receptors that signal to T-cells, and increased production of IL-12, a cytokine that drives T-cell activation. When these YM-2A-primed dendritic cells were loaded with a tumor antigen and used as a vaccine in two separate murine tumor models, tumor growth was significantly reduced and survival improved compared to unprimed DCs.
The significance of the two-pathway finding: maitake's immune effects are not dependent on a single molecule binding a single receptor. The beta-glucan acts through dectin-1; the protein acts through TLR4. Both routes lead to the same result: dendritic cells that are better equipped to activate an adaptive immune response. For a detailed look at the biology of dendritic cells and how each maitake pathway interacts with them, see Maitake and Dendritic Cell Maturation.
The Nanba 2002 Study: What the Foundation Actually Shows
Nanba et al. (2002) remains the primary clinical reference for MD-fraction specifically, and understanding what it does and doesn't show matters for interpreting the broader evidence.[1] Cancer patients across multiple tumor types received MD-fraction alongside their standard chemotherapy regimens. The outcome measure was immune-competent cell activity, a composite measure of immune function derived from peripheral blood, capturing the combined activity of the immune cells circulating in the bloodstream at the time of measurement.
The result: immune cell activity in the MD-fraction plus chemotherapy group was 1.2 to 1.4 times higher than in patients receiving chemotherapy alone. Depending on cancer type, 58 to 69 percent of patients reported symptom improvement.
The essential caveats are real and should be stated plainly. This was a non-randomized, non-blinded study. There was no placebo group. Nanba, as the inventor of MD-fraction, had a direct interest in positive results. These are numbers to be treated as hypothesis-generating evidence rather than established clinical endpoints.
What the study contributed is a clinical context and a set of measurable numbers. It established that immune cell activity is a useful endpoint for maitake research, it defined the magnitude of effect worth testing in controlled conditions, and it pointed subsequent researchers toward the cancer treatment setting as the context where maitake's immune effects might matter most practically.
Dose Matters: The Deng 2009 Finding That Most Coverage Skips
The most rigorous human dose-response study of maitake's immune effects is Deng et al. (2009), a Phase I/II dose-escalation trial published in the Journal of Cancer Research and Clinical Oncology.[6] Thirty-four postmenopausal breast cancer patients received a maitake polysaccharide extract in escalating doses ranging from 0.1 to 5 mg/kg twice daily.
The safety outcome was the study's primary purpose: no dose-limiting toxicity was observed across the entire dose range, establishing a preliminary safety window for maitake extract in cancer patients.
The immune findings were more complicated, and this is the data that most consumer coverage of maitake omits. At moderate doses, immune parameters were stimulated. At higher doses, some of those same immune measures moved in the opposite direction. The strongest and most consistent stimulatory effects appeared at 3 mg/kg twice daily. Above that threshold, some immune markers were suppressed rather than enhanced.
This bidirectional dose-response pattern is not unique to maitake. Many compounds with immunomodulatory activity show this same pattern: some level of stimulation at moderate doses, suppression or dampening at higher doses. It reflects the immune system's regulatory architecture rather than a product flaw. But it does mean that the common framing of maitake as universally "immune-boosting" is an oversimplification. Which immune parameters were measured, at what dose, and in which population all determine what direction the effect goes.
The Deng trial used a general maitake polysaccharide extract rather than a specifically labeled MD-fraction product. The dose-response biology is the same because the active compound is the same beta-glucan, interacting with the same dectin-1 and TLR4 receptors regardless of how it was formulated. The formulation affects absorption; the receptor pharmacology does not change.
The 2022 RCT: The Strongest Clinical Evidence Available
Hu et al. (2022) conducted a randomized clinical trial in patients with advanced laryngeal and pharyngeal cancer undergoing concurrent chemoradiotherapy: the simultaneous combination of chemotherapy drugs and radiation therapy used in advanced head and neck cancers.[7] Patients in the D-fraction group showed improved NK cell and T-cell counts compared to the control group. Side effects from the chemoradiotherapy regimen were also reduced in the D-fraction arm.
This is the most rigorously designed clinical study of D-fraction during active cancer treatment to date. The randomized design is a meaningful step up from the non-randomized Nanba 2002 study. The chemotherapy-plus-radiation context is also more clinically realistic for the patient population most likely to be interested in maitake supplementation.
The limitation: Hu 2022 used D-fraction, not MD-fraction. If the primary question is whether MD-fraction specifically improves immune outcomes during chemotherapy, this trial provides indirect rather than direct evidence. The active compound is the same; the bioavailability may differ; the clinical outcomes may or may not differ as a result.
Earlier animal work by Kurashige et al. (2002) helps explain the mechanism behind these immune cell improvements.[8] D-fraction inhibited tumor growth in mice by coordinating the activation of NK cells, T-cells, and macrophages simultaneously rather than activating a single immune cell type. The multi-cell coordination model that Kurashige established in mice appears to be what Hu 2022 observed in humans: not just NK cells responding, but both NK cells and T-cells improving together.
For a deeper look at how maitake's immune effects relate to recovery during cancer treatment, see Maitake for Immune Recovery After Chemotherapy and Maitake Beta-Glucans and NK Cell Enhancement.
What the Evidence Doesn't Yet Settle
Three important gaps remain in the MD-fraction research base:
The MD-fraction versus D-fraction comparison hasn't been done in humans. The argument for MD-fraction's bioavailability advantage is logical and plausible: a liquid form with vitamin C should absorb better than a dry powder. But the randomized pharmacokinetic trial measuring actual absorption rates of both products in human participants has not been published. The clinical evidence base, including both Deng 2009 and Hu 2022, used D-fraction. The Wu 2021 review describes MD-fraction as having higher bioavailability, but based on formulation theory rather than comparative clinical measurement.
The dendritic cell activation findings are from animal models. The Masuda 2019 and Tsao 2013 studies establish the mechanism in mice. The dectin-1 and TLR4 receptors are conserved across mammals, so the mechanism is biologically plausible in humans. But direct demonstration of maitake-induced dendritic cell maturation in human subjects has not been published. Plausibility and evidence are related but not the same.
Optimal dosing for immune activation is not established. The Deng 2009 dual-effect finding demonstrates that dose direction matters, but that study was designed to find the maximum tolerated dose, not the optimal immunostimulatory dose. The dose at which maitake beta-glucan stimulates versus suppresses immune parameters in different cancer types, treatment contexts, and patient populations is not known from randomized dose-optimization data.
For how maitake compares to other medicinal mushrooms in the broader immune activation landscape, see How Medicinal Mushrooms Activate Macrophages and How Beta-Glucans Epigenetically Reprogram Immune Cells. For the complete picture of D-fraction cancer research, see Maitake D-Fraction and Cancer: The Complete Research Review.
The Bottom Line
Maitake MD-fraction is a liquid formulation of D-fraction's beta-glucan polysaccharide, designed for better absorption through co-administration with vitamin C. The two key clinical studies available, Nanba 2002 and Hu 2022, both used D-fraction rather than MD-fraction specifically, and both showed real but dose-dependent effects on immune cell function. The mechanistic work on dendritic cell activation through dectin-1 and TLR4 is animal-based but biologically plausible. A direct clinical comparison of MD-fraction versus D-fraction in humans remains unpublished.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2RTHM-01455·Wu, Jian-Yong et al. (2021). “Bioactive Ingredients and Medicinal Values of Grifola frondosa (Maitake)..” Foods (Basel.Study breakdown →PubMed →↩
- 3. Source details for this reference are not yet available.
- 4RTHM-01106·Masuda, Yuki et al. (2019). “Maturation of dendritic cells by maitake α-glucan enhances anti-cancer effect of dendritic cell vaccination..” International immunopharmacology.Study breakdown →PubMed →↩
- 5RTHM-00558·Tsao, Yao-Wei et al. (2013). “Characterization of a novel maitake (Grifola frondosa) protein that activates natural killer and dendritic cells and enhances antitumor immunity in mice..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
- 6RTHM-00289·Deng, Gary et al. (2009). “A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects..” Journal of cancer research and clinical oncology.Study breakdown →PubMed →↩
- 7RTHM-01536·Hu, Qinglei et al. (2022). “Effect of Maitake D-fraction in advanced laryngeal and pharyngeal cancers during concurrent chemoradiotherapy: A randomized clinical trial..” Acta biochimica Polonica.Study breakdown →PubMed →↩
- 8. Source details for this reference are not yet available.